Photo of Chelsea Segal

Chelsea Segal

Chelsea Segal's health care practice focuses on regulatory, compliance, and business issues related to telehealth and telemedicine, digital health, pricing and reimbursement, and fraud and abuse. On the life sciences side, Chelsea advises pharmaceutical clients on issues surrounding the regulation of drugs and biologics by the U.S. Food and Drug Administration (FDA), including product approval, advertising and promotion, and communications with payers.

Chelsea routinely advises on administrative and legislative policy developments related to telehealth and telemedicine as well as FDA regulatory issues. She also provides support to clients engaged in life sciences mergers and acquisitions and other commercial transactions, including due diligence.

Chelsea also maintains an active pro bono practice at Covington, with a particular focus on reproductive rights.

Chelsea is an author of a chapter on manufacturer communications with payers in the American Health Law Association treatise, Pricing, Market Access, and Reimbursement Principles: Drugs, Biologicals and Medical Devices.

On Thursday, July 13, 2023, the Centers for Medicaid & Medicaid Services (CMS) released the Calendar Year (CY) 2024 Physician Fee Schedule (PFS) Proposed Rule (CY 2024 PFS Proposed Rule), which proposes policy changes to the PFS and other Medicare Part B issues, effective on or after January 1, 2024.  As explained in our article